# Istanbul University-Cerrahpaşa

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/istanbul-university-cerrahpasa/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 36 |
| Citations | 719,594 |
| City | Istanbul |
| Country | TR |
| Description | Istanbul University-Cerrahpaşa is a research organisation in Istanbul, TR. OpenAlex records 27,995 works and 719,594 citations for it. 8,484 researchers list it as their most recent affiliation. |
| Homepage | https://www.iuc.edu.tr |
| OpenAlex ID | https://openalex.org/I4210112471 |
| Researchers | 8,484 |
| ROR ID | https://ror.org/01dzn5f42 |
| Type | education |
| Works | 27,995 |

## University papers

Showing 12 of 83.

- [Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer](https://scholariq.org/papers/durvalumab-after-chemoradiotherapy-in-stage-iii-non-small-cell-lung-cancer/)
- [Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial](https://scholariq.org/papers/prednisone-plus-cabazitaxel-or-mitoxantrone-for-metastatic-castration-resistant/)
- [Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC](https://scholariq.org/papers/overall-survival-with-durvalumab-after-chemoradiotherapy-in-stage-iii-nsclc/)
- [Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer](https://scholariq.org/papers/abiraterone-plus-prednisone-in-metastatic-castration-sensitive-prostate-cancer/)
- [Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC](https://scholariq.org/papers/atezolizumab-for-first-line-treatment-of-pd-l1-selected-patients-with-nsclc/)
- [Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer](https://scholariq.org/papers/apalutamide-for-metastatic-castration-sensitive-prostate-cancer/)
- [Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial](https://scholariq.org/papers/abiraterone-acetate-plus-prednisone-in-patients-with-newly-diagnosed-high-risk/)
- [Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/survival-with-olaparib-in-metastatic-castration-resistant-prostate-cancer/)
- [Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/pembrolizumab-alone-or-combined-with-chemotherapy-versus-chemotherapy-as-first/)
- [Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study](https://scholariq.org/papers/apalutamide-in-patients-with-metastatic-castration-sensitive-prostate-cancer/)
- [Whole-exome sequencing identifies recessive WDR62 mutations in severe brain malformations](https://scholariq.org/papers/whole-exome-sequencing-identifies-recessive-wdr62-mutations-in-severe-brain/)
- [Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial](https://scholariq.org/papers/four-year-survival-with-durvalumab-after-chemoradiotherapy-in-stage-iii-nsclc-an/)

## University researchers

- [Beyhan Tüysüz](https://scholariq.org/researchers/beyhan-tuysuz/)
- [Deniz Palamar](https://scholariq.org/researchers/deniz-palamar/)
- [Ali Şeker](https://scholariq.org/researchers/ali-seker/)
- [Seha Saygılı](https://scholariq.org/researchers/seha-sayg-l/)
- [Dilek Uludağ Alkaya](https://scholariq.org/researchers/dilek-uludag-alkaya/)
- [Tuğçe Özekli Mısırlıoğlu](https://scholariq.org/researchers/tugce-ozekli-m-s-rl-oglu/)
- [Tuğba Şahbaz](https://scholariq.org/researchers/tugba-sahbaz/)

## University top topics

Showing 8 of 24.

- [Ocular Diseases and Behçet’s Syndrome](https://scholariq.org/topics/ocular-diseases-and-behcet-s-syndrome/)
- [Education Practices and Challenges](https://scholariq.org/topics/education-practices-and-challenges/)
- [Autoimmune and Inflammatory Disorders Research](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders-research/)
- [Inflammasome and immune disorders](https://scholariq.org/topics/inflammasome-and-immune-disorders/)
- [COVID-19 Clinical Research Studies](https://scholariq.org/topics/covid-19-clinical-research-studies/)
- [COVID-19 and Mental Health](https://scholariq.org/topics/covid-19-and-mental-health/)
- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions/)
- [Epilepsy research and treatment](https://scholariq.org/topics/epilepsy-research-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.